Takeda
Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts
March 9, 2020Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma
Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …
Positive CHMP approval for Takeda’s Alunbrig in ALK+ advanced non-small lung cancer
March 4, 2020Research and Development CHMP, EMA, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s
February 28, 2020Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab
Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …
Takeda acquires PvP Biologics after successful Phase 1 study of Celiac Disease treatment
February 26, 2020Research and Development Celiac, PvP, Takeda, phase 1, phase III
Takeda has acquired PvP Biologics following the conclusion of a Phase 1 study of the investigational medicine TAK-062 for the …
Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease
February 17, 2020Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …
Takeda commits to advancing treatments for rare bleeding disorders and cancer
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma
November 8, 2019Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
Strong Phase 3 showing for Takeda’s dengue vaccine, but concerns remain over consistent coverage
November 7, 2019Research and Development Takeda, dengue, pharma
Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in …
Takeda to jettison non-core asset portfolio to Stada for $660 million
November 6, 2019Research and Development, Sales and Marketing Stada, Takeda, pharma
Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …
Redefining the value of medicines with patients at the centre
November 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, health economics and outcomes research, market access, pharma
Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …
Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis
September 27, 2019Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis
Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …
Takeda’s investigational therapy shows promise as cytomegalovirus treatment
September 25, 2019Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma
New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …
Lundbeck and Takeda’s depression drug approved in Japan
September 20, 2019Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma
Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …
NICE recommends Takeda’s Takhzyro for NHS use to prevent hereditary angioedema attacks
September 18, 2019Research and Development, Sales and Marketing NHS, NICE, Takeda, Takhzyro, pharma
UK drug watchdog NICE has announced its final draft guidance recommending Takeda’s subcutaneous injection Takhzyro (Lanadelumab) for use on the …
Takeda signs deal with Sosei Heptares worth $1.2 billion
August 6, 2019Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei
Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
